Title |
Intramuscular versus intravenous anti‐D for preventing Rhesus alloimmunization during pregnancy
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2013
|
DOI | 10.1002/14651858.cd007885.pub2 |
Pubmed ID | |
Authors |
Charles I Okwundu, Bosede B Afolabi |
Abstract |
Antibodies to the red cell Rhesus D (RhD) antigen can be produced during pregnancy in a RhD-negative mother carrying a RhD-positive fetus, in particular following feto-maternal haemorrhage at birth or following any procedure that may cause feto-maternal haemorrhage. While the first baby is usually not harmed, these antibodies may cause haemolytic disease of the fetus/newborn (HDFN) in subsequent RhD-positive babies. RhD incompatibility is a major cause of HDFN.To reduce the risk of HDFN, anti-D is given to RhD-negative mothers at 28 or 30 weeks of pregnancy and within 72 hours of potential maternal exposure to fetal red cells. Anit-D is currently available in both intramuscular (IM) and intravenous (IV) preparations. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Venezuela, Bolivarian Republic of | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Belgium | 1 | <1% |
Australia | 1 | <1% |
Unknown | 108 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 11 | 10% |
Student > Ph. D. Student | 10 | 9% |
Researcher | 10 | 9% |
Student > Postgraduate | 9 | 8% |
Other | 8 | 7% |
Other | 21 | 19% |
Unknown | 41 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 36 | 33% |
Nursing and Health Professions | 12 | 11% |
Psychology | 4 | 4% |
Social Sciences | 4 | 4% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 10 | 9% |
Unknown | 42 | 38% |